BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
路透社2026/10/08 18:26On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
October 8 - ** Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading, closing at $185.91
** RBC Capital Markets stated that the share price decline appears to have been influenced by the latest review documents released by the U.S. Food and Drug Administration (FDA) regarding the company's pancreatic cancer drug Rasonque (link), particularly the disclosure of objective response rate data for the RAS mutation subgroups
** RBC pointed out that overall survival, rather than objective response rate, is a more meaningful measure of efficacy, and that the current sell-off overlooks the broad activity Rasonque demonstrates across various RAS mutation subgroups
** RBC said: “While we acknowledge today’s share price decline is set against the backdrop of weakness in the biotech sector as a whole, we still believe the market’s reaction to the FDA review document is an overreaction, given the drug was approved based on clinically meaningful efficacy and has received positive feedback from physicians.”
** Including intraday volatility, the stock has more than doubled since the beginning of the year
(To facilitate non-native English speakers, Reuters has automated the translation of its reports into several other languages. Since automated translation may contain errors or may not include the required context, Reuters does not guarantee the accuracy of automated translation texts. Automated translation is provided only for the convenience of readers. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Updated Version 2 - SpaceX Targets U.S. Wireless Operators Through Spectrum Acquisition
Reuters, October 8 – SpaceX reached an agreement on Thursday to acquire a nationwide portfolio of low-frequency spectrum, enabling Elon Musk’s satellite business to mount direct orbital competition against traditional U.S. wireless telecom giants. While Starlink Mobile’s existing global 2 GHz mid-band spectrum will provide high bandwidth capacity, this new spectrum will allow its signals to penetrate obstacles. The financial terms of the deal have not been disclosed. This move accelerates billionaire Musk’s ambitions to bypass traditional wireless infrastructure and provide direct cellular network connections to smartphones from orbit. Low-frequency bands are highly valued in telecommunications for their ability to travel longer distances and penetrate dense structures such as walls and tree cover, thereby overcoming a major technical barrier previously faced by satellite mobile networks. The transaction involves the acquisition of 100% of the nationwide 800 MHz spectrum portfolio held by private equity firm Grain Management and is still subject to regulatory approval from the U.S. Federal Communications Commission (FCC). Telecom stocks fell as investors feared competition from SpaceX could trigger a fierce price war and erode their market share in the already saturated U.S. wireless market. The shares of T-Mobile US, Verizon, and AT&T all dropped more than 5% in after-hours trading. The FCC this week also approved Starlink Mobile’s application for a second-generation satellite constellation, authorizing SpaceX to launch 15,000 satellites worldwide optimized for the 2 GHz band. (For the convenience of non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translation may contain errors or may lack required context, Reuters does not guarantee the accuracy of automated translation texts; they are provided solely for readers’ convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)
IWF ETF Declines 1.3%
This article was automatically generated using Dow Jones technology. Shares of iShares Russell 1000 Growth ETF dropped 1.3% to $127.11 Thursday on what proved to be an overall negative trading session for the U.S. stock market, with the S&P 500 Index falling 0.5% to 7,765.36. This was the fund's second consecutive day of losses. The fund's underlying index, the Russell 1000 Growth Index, fell 1.3%. The ETF's shares closed 2.1% below the 52-week high of $129.80 seen on October 6, 2026. Trading volume was 4,726,199, compared to the 65-day average trading volume of 3,881,173. As of October 7, the fund's net asset value totaled $128.81 per share. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 08, 2026 16:36 ET (20:36 GMT)
FactSet Research Systems Inc. Stock Advances 5.0%, Outperforms Peers
This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of FactSet Research Systems Inc. advanced 5.0% to $286.52 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.1% to 51,231.64 and the S&P 500 Index falling 0.5% to 7,765.36. This was the stock's second consecutive day of gains. FactSet Research Systems Inc. closed 10.6% below its 52-week high of $320.48, which the company achieved on September 3rd. The stock outperformed some of its peers, as Alphabet Inc. Cl C fell 0.7% to $344.86, Alphabet Inc. Cl A fell 0.6% to $348.29, and S&P Global Inc. rose 1.91% to $402.73. Trading volume totaled 1.1 million, compared to the 50-day average of 847,281. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 08, 2026 16:34 ET (20:34 GMT)
Crypto prices
More
